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Sexually dimorphic RB inactivation underlies
mesenchymal glioblastoma prevalence in males
Tao Sun,1 Nicole M. Warrington,1 Jingqin Luo,2 Michael D. Brooks,1 Sonika Dahiya,3 Steven C. Snyder,1
Rajarshi Sengupta,1 and Joshua B. Rubin1,4
Department of Pediatrics, 2Division of Biostatistics, 3Department of Pathology and Immunology, and 4Department of Anatomy and Neurobiology, Washington University School of Medicine,

1

St. Louis, Missouri, USA.

The prevalence of brain tumors in males is common but unexplained. While sex differences in disease are typically mediated
through acute sex hormone actions, sex-specific differences in brain tumor rates are comparable at all ages, suggesting
that factors other than sex hormones underlie this discrepancy. We found that mesenchymal glioblastoma (Mes-GBM)
affects more males as the result of cell-intrinsic sexual dimorphism in astrocyte transformation. We used astrocytes from
neurofibromin-deficient (Nf1–/–) mice expressing a dominant-negative form of the tumor suppressor p53 (DNp53) and
treated them with EGF as a Mes-GBM model. Male Mes-GBM astrocytes exhibited greater growth and colony formation
compared with female Mes-GBM astrocytes. Moreover, male Mes-GBM astrocytes underwent greater tumorigenesis in vivo,
regardless of recipient mouse sex. Male Mes-GBM astrocytes exhibited greater inactivation of the tumor suppressor RB,
higher proliferation rates, and greater induction of a clonogenic, stem-like cell population compared with female Mes-GBM
astrocytes. Furthermore, complete inactivation of RB and p53 in Mes-GBM astrocytes resulted in equivalent male and female
tumorigenic transformation, indicating that intrinsic differences in RB activation are responsible for the predominance
of tumorigenic transformation in male astrocytes. Together, these results indicate that cell-intrinsic sex differences in RB
regulation and stem-like cell function may underlie the predominance of GBM in males.

Introduction

Throughout life, there are sex-specific differences in the prevalence
of multiple human diseases. Many of these disparities, such as the
rise in autoimmune diseases in women during their reproductive
years or the increase in cardiovascular diseases in postmenopausal
women, can be related to differences in sex hormone abundance
(1). However, not all sex disparity in human disease correlates with
the dynamics of circulating sex hormones. Regardless of age, brain
cancers are more common in males than in females (2). In fact,
multiple brain tumor types in children exhibit marked sex disparity. For example, group 3 and group 4 medulloblastomas occur in
nearly twice as many boys as girls (3, 4). These tumors occur with
peak incidences in young (<5-year-old) and peripubertal children,
respectively. Thus, while the hormonal milieu of young and peripubertal children is significantly different, there is a potent effect
of sex on tumorigenesis in both age groups. These observations
suggest that the sex disparity in medulloblastoma cannot be simply
ascribed to the effects of circulating sex hormones. Therefore, an
examination of alternate mechanisms through which sex can influence brain tumorigenesis is warranted.
Glioblastoma (GBM), the most common malignant brain
tumor in adults, also exhibits a greater prevalence in men (5).
Despite enormous breakthroughs in basic cancer research,
outcome from GBM remains dismal. For those treated with
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surgery, radiation, and chemotherapy, overall survival remains
approximately 14 months (6). In addition to more frequently
developing GBM, males also have a lower 5-year survival rate
compared with that of females with GBM and other malignant
CNS tumors (7). Understanding how sex affects GBM biology
could elucidate mechanisms relevant to both its genesis and
response to treatment. In the current study, we investigated
whether the effect of sex in GBM involves cell-intrinsic sexual dimorphism in tumor progenitors. Identification of such
cell-intrinsic mechanisms has broad implications for all of cancer biology and cancer care.

Results

Male predominance in GBM is subtype specific. Based on their
gene expression profiles, GBMs can be divided into classical,
mesenchymal, neural, and proneural subtypes (8). The Cancer
Genome Atlas (TCGA) data set, as originally reported by Verhaak et al. (8), indicates that mesenchymal and neural subtypes
of GBM occur in at least twice as many men as women (Table 1).
To determine whether similar sex differences are evident in
other large GBM data sets, we developed methods for sex
assignment based on the genetic signature of the sex chromosomes that could be applied to publically accessible gene expression profiling data, which frequently have incomplete or no sex
information on the samples (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/
JCI71048DS1). We examined 2 additional data sets (GSE16011,
ref. 9, and GSE13041, ref. 10) containing 426 GBM specimens.
jci.org   Volume 124   Number 9   September 2014
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Table 1. Sex-specific rates of GBM molecular subtypes
Molecular subtype
TCGA
Classical
Mesenchymal
Neural
Proneural

Male

Female

Male fraction (95% CI)A

P valueB

18
39
18
33

20
17
8
20

0.47 (0.32, 0.63)
0.70 (0.57, 0.80)
0.69 (0.50, 0.84)
0.62 (0.49, 0.74)

0.8714
0.0046
0.0755
0.0983

23
39
10
36

16
14
3
18

0.59 (0.43,0.73)
0.74 (0.60,0.84)
0.77 (0.49,0.93)
0.67 (0.53,0.78)

0.3368
0.0008
0.0922
0.0198

39
56
29
43

26
32
15
27

0.6 (0.48,0.71)
0.64 (0.53,0.73)
0.66 (0.51,0.78)
0.61 (0.50, 0.72)

0.1366
0.0138
0.048800
0.0722

GSE16011C
Classical
Mesenchymal
Neural
Proneural

GSE13041C
Classical
Mesenchymal
Neural
Proneural

Male fraction equals the ratio of male cases to total cases within each
subtype, and the 95% CI was calculated based on the Agresti-Coull
method. BP values were calculated from 2-sided exact binomial test (H0: P =
0.5 vs. Ha: P ≠ 0.5). CSubtype assignment for subjects in these cohorts was
based on k-nearest neighbor method (k = 9) using TCGA prototype data.
We have varied k in the range of 8~20, and the results are similar.

A

Molecular subtypes were assigned using the k-nearest neighbor
method (with consideration of varying k) based on the prototype
data (8), and missing sex was inferred based on the genetic signature of sex chromosomes. We found that mesenchymal GBM
(Mes-GBM) exhibited significant sex disparity in both data sets,
with the overall rate of affected men greater than twice that of
women. Also evident was a trend toward significantly different
rates in both the neural and proneural subsets, but this was not
evident in the classical GBM. These data suggest that the effect
of sex in GBM is dependent on molecular subtype.
Sex-specific models of gliomagenesis. Mes-GBM frequently exhibits loss of neurofibromin (NF1) and TP53 function (8). Moreover, in
mouse models of disease, combined loss of Nf1 and p53 is sufficient
for gliomagenesis (11), but with a male predominance (12). Thus,
in both mice and humans, sex interacts with loss of NF1 and TP53
as a determinant of glioma, but the molecular basis for this effect
of sex remains unexplained. To investigate whether the effect of
sex on gliomagenesis is independent of the acute actions of sex
hormones, we established male and female astrocyte cultures and
examined their behavior upon stepwise loss of Nf1 and p53.
Male and female astrocytes were isolated from the neocortices of postnatal day 1 Nf1fl/fl GFAP-Cre mice (13, 14). The sex of
resultant cultures was confirmed by expression of the X- and
Y-encoded paralogs Jarid1c and Jarid1d (refs. 15, 16, and Figure 1A),
and complete loss of NF1 expression was verified by Western blot
(Figure 1B). Equal purity of male and female astrocyte cultures was
established by their near uniform expression of astrocyte markers
(GFAP and aldolase C) and the absence of neuronal (NF200) or
oligodendrocyte (CNPase) marker expression (Figure 1C). Male
and female Nf1–/– astrocytes were infected with retrovirus encoding
a flag-tagged dominant-negative form of p53 (DNp53) and EGFP
4124
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(DNp53-IRES-EGFP) (17). DNp53-expressing cells were purified
by FACS based on EGFP expression (Figure 1D). Western blot
analysis indicated that endogenous p53 and the flag-tagged DNp53
construct were similarly expressed in male and female astrocytes
(Figure 1E). Equivalent loss of p53 function in male and female
Nf1–/– DNp53 astrocytes was validated by the parallel reduction
in expression of multiple transcriptional targets of p53, including
Bai1, p21 (also known as Waf1 and Cip1), and Gadd45a (Figure 1F).
After establishing the astrocyte cultures, we first measured the
effects of NF1 and p53 loss on growth in vitro. While male and female
Nf1–/– astrocytes exhibited similar growth rates, the additional loss
of p53 function led to a significantly greater increase in the growth
of male astrocytes compared with female astrocytes (Figure 2A).
These data indicate that sex may influence the functional consequences of tumor suppressor loss in a cell-intrinsic fashion.
Combined in vivo loss of Nf1 and p53 was shown to be sufficient for gliomagenesis in mice (11). To determine whether male
and female Nf1–/– DNp53 astrocytes were transformed, we evaluated their anchorage-independent growth in soft agar colony
formation assays and their tumorigenic potential in intracranial
xenograft assays. Neither male nor female Nf1–/– DNp53 astrocytes formed colonies in soft agar (Figure 2B). Tissue analysis 3
months after intracranial implantation revealed that 2 of 7 mice
with male Nf1–/– DNp53 astrocyte implants and 2 of 7 mice with
female Nf1–/– DNp53 astrocyte implants had tumors (data not
shown). Thus, in this model, sequential loss of NF1 and p53 function is only weakly transforming.
Next, we treated male and female Nf1–/– DNp53 astrocytes
with PDGF or EGF. The PDGF and EGF pathways are frequently
activated in GBM (8, 18–20). The PDGF receptor was equally
expressed in male and female Nf1–/– DNp53 astrocytes, and treatment with PDGF was without sex-specific effects on ERK1/2 and
AKT phosphorylation, soft agar colony formation, or intracranial
tumorigenesis (Supplemental Figure 2).
The EGFR is amplified or mutationally activated in more than
50% of all GBM (21), and EGF can promote transformation in
vitro (22). While EGFR mutational activation and amplification
is most common in classical GBM, it also occurs in nearly 10% of
Mes-GBM (8). Strikingly, EGF treatment resulted in the frequent
formation of large (>100-μm diameter) colonies but only in male
soft agar cultures (Figure 2B). The persistence of green fluorescence in male and female cells throughout the experiment indicated that the failure to transform female cells was not due to the
loss of DNp53 expression. To determine whether the difference in
transformation might be due to differences in EGFR expression
or activation, we treated male and female Nf1–/– DNp53 astrocytes with EGF and measured EGF-induced activation of ERK1/2
and AKT by immunohistochemistry and Western blot. Male and
female Nf1–/– DNp53 astrocytes possessed comparable levels of
and similar cell-to-cell uniformity in EGFR expression and similar
patterns of EGF-induced ERK and AKT phosphorylation (Supplemental Figure 3). Together, these data indicate that both male and
female Nf1–/– DNp53 astrocytes are transformable but that they can
possess different thresholds for in vitro transformation, particularly in response to growth factor stimulation.
To determine whether in vitro sexual dimorphism in transformation would translate to differences in in vivo tumorigenesis, we
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Figure 1. Preparation of male and female Nf1–/– DNp53 astrocytes. (A) Sex determination of isolated mouse astrocytes by PCR for X- and Y-encoded
paralogs Jarid1c and Jarid1d. Shown are results with genomic DNA isolated from adult mouse brain and from 3 independent litters of postnatal day 1 pups.
(B) Western blot analysis of NF1 expression in male and female Nf1fl/fl, Nf1–/–, and Nf1–/– DNp53 astrocytes. Actin served as loading control. (C) Purity of
astrocyte cultures was assessed by immunofluorescence detection of the astrocyte markers aldolase C (red) and GFAP (green) and the absence of neuronal
(NF200) and oligodendrocyte (CNPase) marker expression. Nuclei were counterstained blue with DAPI. (D) Direct fluorescence microscopy of FACS-sorted
cells indicated 100% EGFP expression in male and female Nf1–/– DNp53 astrocytes. (E) Western blot analysis indicated equal expression of endogenous p53
and the flag-tagged DNp53 construct (FLAG). Actin served as loading control. (F) PCR for p53 transcriptional targets Bai1, p21, and Gadd45a indicates equal
loss of expression in Nf1–/– DNp53 astrocytes. ND, not detected; NS, not significant; M, male; F, female. Scale bar: 100 microns.

implanted male and female EGF-treated Nf1–/– DNp53 astrocytes
into the brains of both male and female nude mice. In contrast to
the minimal tumorigenic potential of untreated and PDGF-treated
male and female Nf1–/– DNp53 astrocytes, 100% of recipient mice
(14 of 14 male, 8 of 8 female) implanted with male EGF-treated Nf1–/–
DNp53 cells developed tumors and succumbed to disease (Figure
3A). Strikingly, only 36% of recipient mice (5 of 14 male and 3 of
8 female) implanted with female EGF-treated Nf1–/– DNp53 cells
developed tumors and died (P < 0.0001, log-rank test). Tumors
were recognizable in situ by their EGFP fluorescence (Figure 3B),
confirming persistent transgene (DNp53) expression. Pathological
evaluation diagnosed the tumors as high-grade gliomas based on
GFAP expression, nuclear atypia, mitoses, and necrosis (ref. 23
and Figure 3C). Notably, there were no histological distinctions
between tumors derived from male and female cells (Supplemental Figure 4, A and B). The presence of viable EGFP-positive cells
at the injection sites in brains of asymptomatic mice harboring
female Nf1–/– DNp53 implants indicated that graft failure and loss
of DNp53 expression were not reasons for the lack of tumor formation (Supplemental Figure 4, C and D).

The in vivo results suggested that intracranial tumorigenesis
was determined by the sex of the implanted cells and not by the
sex of the recipient mouse. To directly test whether the sex of the
microenvironment and circulating sex hormones influence tumorigenesis, we simultaneously implanted male and female EGFtreated Nf1–/– DNp53 astrocytes into the flanks of 8 male and 9
female NCR nude mice. Twelve of seventeen male implants (71%)
formed tumors (Figure 3D) equally in male (5 of 8) and female (7
of 9) recipient mice (P = 0.62, Fisher’s exact test). Six of seventeen
female implants (35%) formed tumors, again without difference
between male (3 of 8) and female (3 of 9) recipient mice (P = 1,
Fisher’s exact test). Moreover, male cells exhibited significantly
greater maximal tumor growth (Figure 3E). Thus, in both the
intracranial and flank locations, male EGF-treated Nf1–/– DNp53
astrocytes more readily formed tumors than their female counterparts, regardless of the sex of the surrounding tumor microenvironment. These data demonstrate that, in this model, sex-specific
thresholds exist for transformation and that cell-intrinsic differences, rather than the sex of the microenvironment, are the stronger determinants of tumor growth.
jci.org   Volume 124   Number 9   September 2014
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Figure 2. Male predominant in vitro transformation of mouse astrocytes with inactivation of NF1 and p53. (A) In vitro growth of male
and female Nf1–/– astrocytes and Nf1–/– DNp53 astrocytes over 4 days.
Shown are best fits of an exponential growth curve to all data points
(***P = 0.0004, ANOVA). (B) EGF treatment (50 ng/ml) supported colony
formation (asterisks) in soft agar with male but not female Nf1–/– DNp53
astrocytes. Scale bar: 200 μm.

Mechanisms of sexually dimorphic transformation. To understand why male astrocytes may be more susceptible to malignant transformation, we first measured the clonogenic subpopulation. Loss of p53 function can enhance self-renewal and the
reacquisition of a multipotent stem-like cell state (24), which
may be essential for malignant transformation of differentiated
cells (25). Clonogenic cell frequency, as measured by extreme
limiting dilution assays (ELDA) (26), ranged from 6.1% to 17.6%
in male Nf1–/– DNp53 astrocytes and 1.6% to 3.4% in female Nf1–/–
DNp53 astrocytes (Figure 4, A and B). The greater stem-like cell
frequency in male Nf1–/– DNp53 cells was associated with higher
expression of stem cell markers CD133 and Sox2 (Figure 4C) as
well as the capability of forming larger and greater numbers of
neurospheres (Figure 4D).

Next, we asked whether sex differences in stem-like cell activity were a result of p53 inactivation or whether they preexisted as a
consequence of Nf1 loss. The frequency of clonogenic cells in Nf1–/–
postnatal day 1 hippocampal neural stem cells (NSCs) was approximately 2%, and no differences were observed between male and
female cultures (Figure 4E). To determine whether sex differences
might emerge with differentiation, we measured clonogenicity in
Nf1–/– astrocytes. Both male and female Nf1–/– astrocytes possessed
an equivalently low frequency (0.2%) of cells with clonogenic
potential (Figure 4F). Thus, sex differences in clonogenic stemlike cell properties between male and female Nf1–/– DNp53 astrocyte cultures are a result of sexually dimorphic response to the loss
of p53 function.
To further dissect the mechanistic basis for sex differences
in transformation, we examined rates of apoptosis and proliferation in cultured male and female Nf1–/– DNp53 astrocytes. Apoptosis was measured by quantifying levels of cleaved caspase-3
under basal conditions and after etoposide treatment. While
there was a trend toward greater basal and etoposide-induced
apoptosis in male Nf1–/– DNp53 astrocytes, this did not reach
statistical significance (Figure 5A). To measure proliferation, we
quantified the percentage of nuclei positive for phospho-histone
H3 (pHH3), a widely used proliferation marker in gliomas (27).
We found that male Nf1–/– DNp53 astrocytes exhibited significantly higher levels of pHH3 positivity compared with female
Nf1–/– DNp53 astrocytes (Figure 5B), indicating that they possess
a higher rate of proliferation.

Figure 3. Male predominant in vivo tumorigenesis occurs irrespective of recipient mouse sex. (A) Intracranial implantation of EGF-treated male (n = 22)
and female (n = 22) Nf1–/– DNp53 astrocytes from 3 independent litters resulted in death of 100% of mice receiving male cell implants and 36% of mice
receiving female cell implants (***P < 0.0001, log-rank test). (B) Intracranial tumors were recognizable in situ by their EGFP expression (asterisk). (C) Intracranial tumors exhibited features of GBM, including nuclear pleomorphism and pseudopalisading necrosis (asterisk, top row), GFAP positivity, and abundant mitoses (asterisk, bottom row). Scale bar: 20 microns. (D) Male (black arrows) and female (white arrows) EGF-treated Nf1–/– DNp53 astrocytes were
implanted into the flanks of male and female mice. Male cells gave rise to more tumors regardless of the recipient mouse sex. (E) Flank tumor volumes
measured by calipers at 6 weeks. Each symbol represents an individual tumor. Mean volumes were significantly different (**P = 0.001, Wilcoxon rank test).
4126

jci.org   Volume 124   Number 9   September 2014

Downloaded October 4, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI71048.

The Journal of Clinical Investigation  

Research article

dependent transcription and more
rapid transit from G1 to S phase. To
determine whether the differences
in RB phosphorylation had functional consequences, we examined
E2F-dependent transcription and
cell cycle distribution in male and
female Nf1–/– DNp53 astrocytes
upon addition of sera. To measure
E2F-dependent transcription, we
constructed a lentiviral reporter
system with 3XE2F-driven luciferase expression (Supplemental Figure 5) and established stable lines of
male and female Nf1–/– DNp53 E2FLuc reporter cells. Male and female
Nf1–/– DNp53 E2F-Luc reporter cells
were serum starved for 24 hours
and then treated with 10% serumsupplemented media for 6 hours.
As cell number was linearly related
to EGFP fluorescence (Figure 6C,
inset), we were able to normalize
E2F-Luc reporter activity to EGFP
measures. Consistent with the
Figure 4. Sex differences in induction of a stem-like cell subpopulation in Nf1–/– DNp53 astrocytes. (A) Fremeasured differences in RB phosquency of clonogenic (stem-like) cells was measured by ELDA in Nf1–/– DNp53 cells (3,000, 600, 120, 24, 5, and 1
phorylation, male Nf1–/– DNp53
cell per well; 10–12 replicates per dilution), with 3 independent astrocyte preparations. Shown is a representative
astrocytes exhibited a greater level
ELDA analysis from one of the three cell preparations. CSC, clonogenic (stem-like) cell. (B) Male Nf1–/– DNp53
cells have a significantly higher stem-like cell frequency (12.2% ± 3.4%) than female (2.77% ± 0.6%) counterof E2F-Luc activity in response to
parts, as derived from the ELDA analysis (*P = 0.03, t test). (C) Sex differences in expression of stem cell markserum (Figure 6C). As expected, sex
ers CD133 and Sox2 (*P = 0.018 and **P = 0.03 for CD133 and Sox2 respectively, 2-tailed t test). (D) Representadifferences in RB phosphorylation
tive images of neurospheres from male and female Nf1–/– DNp53 cells (3,000 cells per well) 1 week after plating.
and E2F reporter activity were corScale bar: 500 microns. (E) The frequency of clonogenic stem-like cells, as determined by ELDA, was equal in
related with differences in cell cycle
male (2.49% ± 1.1%) and female (1.73% ± 0.63) Nf1–/– NSCs. (F) The frequency of clonogenic stem-like cells, as
determined by ELDA, was equally low (0.2%) in both male and female Nf1–/– astrocytes.
regulation. While serum starvation
significantly increased the G1 fraction in female Nf1–/– DNp53 astroNext, we performed cell cycle analysis. Under basal asynchrocytes, it produced no significant G1 change in male Nf1–/– DNp53 astro–/–
nous conditions, the fraction of male Nf1 DNp53 astrocytes in
cytes, indicating that male cells possessed lower RB activity (Figure
6D). Together, these findings strongly indicate that RB regulation is
the S and G2/M phases of the cell cycle was greater than in their
sexually dimorphic in Nf1–/– DNp53 astrocytes and that the functional
female counterparts (Figure 5C). To understand why male Nf1–/–
DNp53 astrocytes exhibited greater proliferation and S/G2/M cell
consequences of this include greater proliferation in male cells.
To test whether differential inactivation of RB underlies sex
cycle distribution, we examined regulation of the retinoblastoma
differences in transformation, we expressed SV40 large T antigen
protein (RB) pathway. The RB pathway is a negative regulator of
(SV40-TAg) in male and female Nf1–/– astrocytes (29). SV40-TAg
proliferation, and RB loss or inactivation is among the most common features of human cancers (28). To assess RB regulation, we
completely inactivates both p53 and RB pathways (reviewed in ref.
serum starved male and female Nf1–/– DNp53 astrocytes to promote
30). Quantitative PCR verified equal SV40-TAg expression and
equivalent reductions in expression of p53 transcriptional targets
arrest in the G1 phase of the cell cycle and then followed RB phosp21 and Gadd45a and expected increases and decreases in expresphorylation (inactivation) and cell cycle progression after adding
sion of E2F targets Cdc6 (31) and Bcl2 (32), respectively (Figure
serum back. Western blot analysis indicated that, under condi7A). In soft agar assays, we found that, in contrast to EGF-treated
tions of serum starvation, male and female Nf1–/– DNp53 astrocytes
Nf1–/– DNp53 astrocytes, both male and female Nf1–/– SV40-TAg
expressed comparable levels of RB and phosphorylated RB (Figure
–/–
6, A and B). Upon addition of serum, male Nf1 DNp53 astrocytes
astrocytes were competent to form colonies (Figure 7B). Moreover,
both male and female Nf1–/– SV40-TAg astrocytes formed tumors
exhibited significantly greater time-dependent phosphorylation
of RB compared with that of female astrocytes.
of similar sizes upon flank implantation (Figure 7C), regardless of
RB regulates transition from the G1 to the S phase of the cell
the sex of recipient mice. These data indicate that under conditions of equivalent combined loss of p53 and RB function, male
cycle through sequestration of E2F transcription factors. Hyperphosphorylation of RB or loss of RB expression results in increased E2F- and female astrocytes are equally transformed.
jci.org   Volume 124   Number 9   September 2014
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Figure 5. Sex differences in proliferation of Nf1–/– DNp53 astrocytes. (A) Protein lysates of male and female Nf1–/– DNp53 astrocytes
treated with DMSO or etoposide (10 μg/ml, 24 hours) were analyzed by
Western blot for cleaved caspase-3 and total caspase-3. Actin served
as loading control. A single representative blot and quantitation from
the 3 independent experiments are shown. (B) Representative fields
from cultures of male and female Nf1–/– DNp53 astrocytes stained with
hematoxylin and for the presence of the nuclear proliferation marker
pHH3 (brown). Blue arrowheads identify examples of nuclei negative for
pHH3. Red arrowheads identify examples of nuclei positive for pHH3.
Scale bar: 100 microns. Quantification of the percentage of positive
nuclei is shown (*P < 0.05, t test). (C) Representative histograms from
male and female Nf1–/– DNp53 astrocyte cell cycle analysis of asynchronously growing serum-supplemented cultures. Quantified areas
for each phase of the cell cycle are as indicated. Means for cell cycle
distribution from 3 independent cultures are shown.

Discussion

Sex differences in the incidence and progression of human disease
are increasingly recognized as clinically significant and mechanistically important. While the acute actions of sex hormones are recognized as critical determinants of many aspects of normal biology and
pathology, here we provide the first evidence that cell-intrinsic sex
differences can render male and female cells differentially sensitive
to malignant transformation. Among the immediate implications of
this work is that the potential for sex-specific effects should be considered when evaluating oncogenic mechanisms. This approach is likely
to illuminate new details of cancer cell biology and could modify our
approach to cancer surveillance, disease stratification, and treatment.
Male, but not female, astrocytes with complete loss of NF1
and p53 function were poised for transformation by activation of growth factor pathways. Differences in transformation
were related to a greater susceptibility for RB inactivation and
increased induction of a stem-like cell phenotype in male astrocytes compared with female astrocytes. The equal transformation of male and female astrocytes in the setting of complete RB
and p53 inactivation, as well as the equal incidence of classical
GBM in males and females, indicate that sex differences in GBM
and other cancers may be confined to specific subsets of disease.
4128
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Loss of NF1 and p53 function resulted in a greater rate of
growth and a significant elevation in the fraction of clonogenic
cells in male astrocytes compared with female astrocytes. Both
effects can be related to the observation that male Nf1–/– DNp53
astrocytes exhibited greater inactivation of RB. A focus on RB as
the mediator of sex differences in transformation in this model
is supported by contrasting the effects of p53 loss alone (DNp53)
to those after combined loss of p53 and RB (SV40-TAg). When
p53 function was abrogated but RB was left intact, significant
sex differences were apparent in 4 measures: (a) RB inactivation
in response to serum, (b) proliferation rates, (c) stem cell induction, and (d) transformation in response to EGF. When RB and
p53 were completely inactivated there was no sex difference in in
vitro transformation or tumorigenicity in vivo. These observations
strongly suggest that sexual dimorphism in the regulation of RB
function can contribute to sex differences in cancer. It is interesting to note that the incidence of retinoblastoma, in which there is
complete inactivation of RB, is equal between males and females
(33). It is similarly interesting to consider the frequent deletion of
CDKN2A in classical GBM (8) and whether this potent mechanism
of RB inactivation is related to the equal incidence of classical
GBM in males and females.
Differential RB inactivation may also underlie the observed
differences in clonogenic cell activity. While RB’s role in regulating cell cycle progression has been known for decades (34), its role
in stem cell function has only been recognized recently. Loss of RB
function in stem and progenitor cell populations results in multiple cell autonomous abnormalities, including loss of quiescence,
hyperplasia, increased apoptosis, defective terminal differentiation, and tumorigenesis (for review ref. 35).
Future studies will need to address whether cell-intrinsic sex
differences in transformation will be equally apparent in models involving alternate cells of origin, different transformation
paradigms, and in different mouse strains. Mounting evidence
indicates that GBM can arise from NSCs, oligodendrocyte progenitors, and differentiated glial and neuronal cells (25, 36, 37). It
will be important to determine whether each potential cell of origin exhibits similar sex differences and, if not, to investigate the
mechanisms through which sex and cell type interact.
Similar to what we observed with untreated Nf1–/– DNp53
astrocytes, Zhu et al. found that loss of NF1 followed by loss of p53
function did not result in tumorigenesis (11). However, when p53
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Figure 6. Sex differences in RB inactivation in Nf1–/– DNp53
astrocytes. (A) Western blot analysis for RB and phospho-
RB (p-RB) in protein lysates from cultures of male and
female Nf1–/– DNp53 astrocytes serum starved for 48 hours
(t = 0) and after addition of serum for the indicated times.
Actin served as loading control. Shown are representative
blots from 1 of 3 independent experiments. (B) Quantification of Western blot analysis of RB phosphorylation. Shown
is the ratio of p-RB/RB as a function of time in serum
(***P = 0.0001, ANOVA). (C) RB inactivation was mesured
with an E2F-Luc reporter in 4 independent cultures
of male and female Nf1–/– DNp53 astrocytes. For each
measurement, bioluminescence was normalized to EGFP
fluorescence, which was linearly related to cell number in
both male and female astrocytes (inset). Male values were
normalized to female values within each experiment
(*P < 0.05, t test). (D) G1 fraction obtained from cell cycle
analysis of male and female Nf1–/– DNp53 astrocytes cultured in serum or serum starved for 48 hours. Quantitation
of 4 independent experiments is shown (*P = 0.028, t test).

function was abrogated prior to deletion of Nf1, high-grade gliomagenesis ensued in 100% of mice without apparent sex disparity. It
would be interesting to determine whether additional tumor-promoting events, like activation of the EGFR pathway, would reveal
sex differences in tumorigenesis in mice with inactivation of NF1
and p53 function under various conditions.
High-grade gliomagenesis in the setting of combined NF1 and
p53 loss has also been modeled in NPcis mice, which carry a genetic
construct of tightly linked mutant alleles of NF1 and p53 (38). Similar to our results, when NPcis mice were maintained on a C57BL/6J
background, high-grade gliomas occurred with a male predominance (12, 39, 40). Importantly, 129S4/SvJae mice were highly
resistant to the gliomagenic effects of NPcis mutations. While modifier loci for the strain- and sex-specific effects have been mapped,
the mechanisms by which they modify gliomagenesis have not been
defined. It will be important to determine whether there are similar
strain effects in our model as well as whether any of the loci involved
in the effects of sex encode components of the RB pathway.
Finally, while the current data extend our understanding of
how cell-intrinsic sexual dimorphism can contribute to sex differences in cancer, they do not diminish the potential role of sex
hormones in oncogenesis, cancer progression, and response to
therapy. Thus, future studies, particularly those involving models, such as the 4-core genotypes model of sex differences, will
be especially important for illuminating the contributions of both
chromosomal and gonadal sex to cancer biology (41).

Methods
Chemicals, media, and sera
Unless otherwise stated, all chemicals were purchased from Sigma-
Aldrich, and all tissue culture media was obtained from Invitrogen.
Sex determination in publically accessible gene expression data sets
Detailed methods for sex determination in gene expression data sets
are provided in the legend to Supplemental Figure 1.

Male and female astrocyte cultures
Primary cultures of astrocytes were prepared from the neocortices of
individual postnatal day 1 Nf1fl/fl GFAP-Cre mice and cultured in DMEM/
F12 supplemented with 10% FBS as previously described (14, 42). Nf1fl/fl
GFAP-Cre mice were a gift from David Gutmann (Washington University School of Medicine). The sex of each mouse was determined from
tail DNA by PCR for Jarid1c and Jarid1d (15, 16). All male and female cells
from at least a single litter with the same genotype were pooled. Replicate experiments were performed using low-passage (≤6) astrocytes
isolated from at least 3 independent litters. Purity of astrocyte cultures
was determined by immunolabeling for specific markers for astrocytes
(GFAP [1:250, Invitrogen] and aldolase C [1:200, Santa Cruz]), neurons
(NF200 [1:250, Sigma-Aldrich]), and oligodendrocytes (CNPase [1:500,
Sigma-Aldrich]). Immunolabeling was detected with Alexa Fluor 555–
or 488–conjugated secondary antibodies (Molecular Probes). Nuclei
were counterstained with DAPI (1:10,000). Fluorescent images were
obtained using an inverted fluorescent microscope (IX51, Olympus).
Isolation of Nf1–/– NSCs
Nf1–/– NSCs were isolated from the hippocampi of Nf1fl/fl GFAP-Cre
postnatal day 1 pups. Briefly, the hippocampus was dissected out of
whole brain and incubated in digest media for 10 minutes at 37°C as
previously described (43). Cells from each hippocampus were maintained separately in neurosphere media (neurobasal medium supplemented with N2, B27, EGF, bFGF, and LIF) until the sex of the pups
was identified by PCR. Single cell suspensions were prepared with trituration and passed through a 40-μm cell strainer.
Expression of DNp53 and SV40-TAg in Nf1–/– astrocytes
DNp53-IRES-EGFP–encoding retrovirus was generated by transfecting Plat-E cells (gift from Steven Teitelbaum, Washington University
School of Medicine) with a pMIG-DNp53-EGFP construct provided by
Emily Cheng (Memorial Sloan-Kettering Cancer Center, New York,
New York, USA). The resultant viral media were used to infect male
and female Nf1–/– astrocytes with polybrene (5 μg/ml). Nf1–/– DNp53EGFP–positive cells were sorted to purity using a MoFlo high speed
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Figure 7. Male and female astrocytes are equally transformed upon inactivation of both p53 and RB by SV40-TAg. (A) Quantitative PCR for SV40-TAg,
the p53 transcriptional targets p21 and Gadd45a, and the E2F targets Cdc6 and Bcl2. (B) Representative images from tumorsphere cultures of male and
female Nf1–/– SV40-TAg astrocytes. Scale bar: 200 microns. (C) Male and female Nf1–/– SV40-TAg astrocytes yielded equal numbers of equivalently sized
tumors upon flank implantation. Each symbol represents an individual tumor.

flow cytometer (Beckman Coulter). SV40-TAg retrovirus was similarly
generated using pBabe-Neo-SV40-TAg plasmid provided by Sheila
Stewart (Washington University School of Medicine). After infection,
the Nf1–/– SV40-TAg astrocytes were selected by G418 (250 μg/ml)
containing media for 4 weeks. SV40-TAg expression was confirmed by
quantitative RT-PCR in resultant G418-resistant clones.

Growth assays
Nf1–/– or Nf1–/– DNp53 astrocytes were grown in 6-well plates (20,000
cells per well). Viable cell numbers were measured every 24 hours by
Trypan Blue exclusion (final concentration 0.1%) using a Cellometer
Auto T4 cell counter (Nexcelom Bioscience) with triplicate wells per
time point per sex.
Soft agar assays
Colony formation assays were performed in soft agar plates as
described previously (29). Briefly, 0.6% Difco Noble Agar (BD Bioscience) in DMEM/F12 media with 10% FBS was plated on the bottom layer and 0.3% agar was plated on the top layer, which contained
astrocytes. In some experiments, astrocytes were treated with EGF
(50 ng/ml, Sigma-Aldrich) or PDGF-BB (20 ng/ml, Sigma-Aldrich) for
a week prior to the assays. EGF or PDGF was also added to the soft
agar when cells were plated, and colony formation was evaluated 3 to
4 weeks later based on EGFP expression.
Limiting dilution assays
Male and female Nf1–/– NSCs, Nf1–/– astrocytes, and Nf1–/– DNp53 astrocytes were diluted to various densities (3,000, 600, 120, 24, 5, and
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1 cell per well) in neurosphere media and plated in 96-well ultralow
cluster plates (Corning), with 10 to 12 wells per concentration. Sphere
formation was measured 7 days after plating. Clonogenic stem-like
cell frequency was analyzed using the Extreme Limiting Dilution
Analysis (http://bioinf.wehi.edu.au/software/elda/).

Tumorigenesis assays
Nf1–/– DNp53 astrocytes treated with 50 ng/ml EGF were implanted
either into the brains or flanks of nude mice. For intracranial implantations, 100,000 cells were stereotactically implanted to the cerebral cortices of nude mice as described previously (44). Mice with intracranial
tumors were sacrificed when symptomatic. For flank implantations, 1
million male or female Nf1–/– DNp53 cells in 50 μl Matrigel (BD Bioscience) were implanted in the left or right flank, respectively, of the same
mouse. Flank tumors were measured weekly with a digital caliper.
Cell cycle analysis. Ethanol-fixed cells were washed in PBS plus
0.1% FBS and resuspended in propidium iodide–staining (PI-staining)
solution containing 0.1% Triton X-100, 0.25 mg/ml DNase- and protease-free RNase A, and 10 μg/ml PI in PBS. Cells were incubated for 1
hour at room temperature in the dark and filtered through a 35-micron
cell strainer. Flow cytometry was done on a FACSCalibur system (Becton Dickinson). Data were analyzed using CellQuest software (Becton
Dickinson). Aggregates and debris were excluded from the analysis.
Quantitative real-time PCR
Quantitative PCR assays were performed using SYBR Green 2x PCR Master Mix (Applied Biosystems). cDNA was generated from total RNA with
SuperScript III Reverse Transcriptase (Invitrogen) per the manufacturer’s
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instructions. PCR and data collection were done using the Bio-Rad Mini
Opticon Real-Time PCR machine and Opticon Monitor 3 software from
Bio-Rad (Hercules). Relative transcript copy number for each gene and
corresponding GAPDH sample were calculated using the ΔΔC(t) method.
PCR primers used in these studies are listed in Supplemental Table 1.

Western blotting
Western blots were performed using the Odyssey Infrared Imaging
system (LI-COR) as previously described (45). Total protein (30~50 μg
per lane) was loaded onto a 4% to 12% Nu-Page gradient gel (Invitrogen) for most experiments, except for the detection of NF1 (150 μg total
protein per lane). Primary antibodies were incubated at 4°C overnight,
except for mouse anti–β actin (1:40,000, Sigma-Aldrich), which was
incubated at room temperature for 1 hour. Secondary antibody incubation was at room temperature for 1 hour. Primary antibodies used
in this study were rabbit anti-NF1 (1:200, Santa Cruz), goat anti-p53
(1:500, Santa Cruz), mouse anti-FLAG (1:1,000, Sigma-Aldrich).
For evaluation of EGF and PDGF signaling pathways, male and
female Nf1–/– DNp53 astrocytes were serum starved for 24 hours and then
treated with EGF (50 ng/ml) or PDGF-BB (20 ng/ml) for the indicated
times. Western blots were performed as described above using antibodies from Cell Signaling Technology (CST): rabbit anti-EGFR (1:500),
rabbit anti-PDGFR β (1:1,000), rabbit anti-pAKT (1:500), pERK1/2
(1:1,000), mouse anti-pan AKT (1:500), and pan ERK1/2 (1:1,000).
For evaluation of RB phosphorylation, male and female Nf1–/–
DNp53 astrocytes were serum starved for 48 hours and then treated
with 10% serum-supplemented media for the indicated times. Western blots were performed as described above with the following antibodies from CST: rabbit anti-RB (1:800) and rabbit anti-phosphorylated RB (S807/811, 1:1,000).
Immunohistochemistry
Tissue. Mouse brains were perfused with PBS followed by 4% paraformaldehyde. After paraffin embedding, tissue was sectioned for
standard hematoxylin and eosin and immunohistochemical staining
as previously described (45).
Cell culture. Male and female Nf1–/– DNp53 cells were grown on
coverslips for 48 hours, followed by 24-hour serum starvation before
EGF (50 ng/ml) treatment. Cells were fixed with 4% paraformaldehyde for 15 minutes and permeabilized with 0.1% Triton-X 100 for 30
minutes at room temperature, and nonspecific antibody staining was
blocked with normal serum. Immunodetection was performed as previously described with antibodies specific for phospho-ERK1/2 (rabbit
IgG 1:500, CST) and EGFR (rabbit IgG 1:50, CST). Nonspecific rabbit
IgG control served as control.
pHH3 staining
Cell proliferation was measured by pHH3 (Ser10) immunolabeling.
Male and female Nf1–/– DNp53 astrocytes were cultured for 48 hours
on coverslips precoated by Poly-l-Lysine and Poly-Ornithine (Sigma-
Aldrich). Cells were prepared for immunolabeling, and immunohistochemistry was performed following standard procedures using
rabbit anti-pHH3 (CST; 1:500 with 1% BSA and biotin). After DAB
development, coverslips were rinsed with PBST and mounted in
Immuno Mount (GeneTex). Cells with positive pHH3 staining were
counted by ImageJ. Final results were obtained from >1,000 cells per
sex derived from 3 independent litters.
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Etoposide-induced caspase-3 cleavage
Cleaved caspase-3, measured by Western blot, was used as an indicator for apoptosis. Male and female Nf1–/– DNp53 astrocytes were
treated with either DMSO or etoposide (10 μg/ml) for 24 hours, and
cell lysates were harvested for Western blotting. Intact and cleaved
caspase-3 were detected with rabbit anti–caspase-3 (1:600, CST) and
anti-cleaved caspase-3 (1:400, CST).
E2F-Luc reporter assay
To construct the lentiviral E2F-Luc reporter system, we first inserted
3XE2F binding sites (46), provided by Wilhelm Krek (ETH Zurich) and
Hans Rotheneder (Medical University of Vienna, Vienna, Austria),
into the pGL4.26 (Promega) reporter construct. The DNA fragment
encoding 3XE2F-Luc (including the upstream poly-A signal) and the
SV40 promoter-hygromycin resistance gene (including the downstream poly-A sequence [HygR]) were amplified by PCR using primers
with 5′-NdeI and 3′-EcoRI linkers. Subsequently, a fragment encoding
the CMV promoter-GFP cassette of the pRRLsinCMV-GFP vector
(47) was removed by NdeI and EcoRI digestion and replaced with the
3XE2F-Luc SV40-HygR encoding PCR product. E2F-Luc lentivirus
was prepared from the final pRRLsin-E2F-Luc by cotransfecting 293T
cells with both pRRLsin-E2F-Luc construct and the packing plasmids
(Delta8.9 and VSV-G) as described previously (48). Viral media were
collected 48 hours after 293T transfection, and media were centrifuged, followed by filtering through a 0.44-μm filter, before infecting
Nf1–/– DNp53 astrocytes. Stable male and female E2F-Luc–expressing
Nf1–/– DNp53 astrocytes were established by hygromycin (250 μg/ml)
selection for 3~4 weeks.
A linear correlation between EGFP expression and cell number
was established by serial dilution of reporter astrocytes from 3 independent litters (4 replicate wells per concentration per sex per preparation) in a 96-well plate with white walls (Costar). EGFP signals
were read 3 hours after plating using a Synergy Neo HTS Multi-Mode
microplate reader (Biotek), and EGFP signals were plotted against
actual cell number.
E2F reporter activity was measured in male and female Nf1–/–
DNp53 E2F-Luc astrocytes that had been serum starved for 24 hours
and then stimulated or not with 10% FBS in phenol red–free DMEM/
F12 for 6 hours. At 6 hours after serum treatment, total EGFP fluorescence per well was measured as described above. Total luciferase
activity was measured using the One-Glo Luciferase Assay System
(Promega) according to the manufacturer’s guidelines. Total luciferase activity was normalized to total EGFP fluorescence. For each treatment condition, 4 replicate wells per sex per preparation were read,
and the final results were from 4 independent biological replicates of
male and female reporter astrocyte cultures.
Statistics
Student’s t test was used to compare quantitative measurements
between 2 groups. ANOVA was used to analyze differences in in vitro
longitudinal growth and RB phosphorylation between sexes. Tumor
formation by sex was compared by Fisher’s exact test. Sex-dependent
differences in flank tumor size were evaluated with Wilcoxon rank
test. Log-rank test was used to determine sex differences in survival
between mouse groups with intracranial implantation of either male
or female Nf1–/– DNp53 cells. All tests were 2 sided, and a P value of
less than 0.05 was considered significant. All quantitative data are
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presented as the mean and SEM of 3 independent experiments, using
astrocytes derived from at least 3 independent litters of mice. Data
were analyzed using GraphPad Prism version 4.00 (GraphPad Software) and R version 2.15.2 (http://cran.r-project.org).

Study approval
Animals were used in accordance with an animal studies protocol (no.
20120174) approved by the Animal Studies Committee of the Washington University School of Medicine per the recommendations of the
Guide for the Care and Use of Laboratory Animals (NIH).
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